Finance Watch: GondolaBio, BridgeBio’s Second Spinout Of 2024, Launches With $300m
Big Private, Public Financings Despite Summer Slowdown
BridgeBio spun out oncology assets in May to focus on rare diseases and now it has sliced off a few rare disease candidates for GondolaBio. Also, Avidity and Kymera closed follow-on offerings that grossed $345.1m and $225m, respectively, and Vandria extended its series A round to $30.7m.
